Pharma Focus Asia
Klöckner Pentaplast - Pentapharm® alfoil® films

Novel Ivonescimab (PD-1/VEGF Bispecific Antibody Developed for Non-Small-Cell Lung Carcinoma (NSCLC) patients

Akeso Biopharma developed novel Ivonescimab (PD-1/VEGF bispecific antibody in combination with docetaxel for the treatment of locally advanced or metastatic Non-Small-Cell Lung Carcinoma (NSCLC) patients.

Novel Ivonescimab is applicable for patients who have failed to respond to prior PD-(L)1 inhibitor combined with platinum-based doublet chemotherapy.

Ivonescimab is the first-in-class PD-1/VEGF bi-specific antibody blocking PD-1 binding toPD-L1 and PD-L2 and it also blocks VEGF binding to VEGF receptors. When PD-1 antibody combined with VEGF blocking agents have shown efficient results in different tumors such as renal cell carcinoma, non-small cell lung cancer and hepatocellular carcinoma.

Ivonescimab, as a single agent can block these two VEGF and PD-1 antibodies and enhance the antitumor activity, compared to combination therapy.

To treat EGFR-mutatedlocally advanced or metastatic NSCLC patients, AK112 is combined with chemotherapy, failed to respond to EGFR-TKI treatment, having completed Phase III clinical trials patient enrollment.

PD-1/L1 monoclonal antibody in combination with platinum-based chemotherapy is the first-line therapy for patients with advanced NSCLC.

AK112 is the only drug candidate approved for NSCLC patients with PD-(L)1 resistant lung cancer treatment in China.

China National Medical Products Administration (NMPA) grants Breakthrough Therapy Designation (BTD) for Ivonescimab (PD-1/VEGFbispecific antibody for Non-Small-Cell Lung Carcinoma (NSCLC).

magazine-slider-imageBIOVIA from Molecule to MedicineMFA + MMA 2024CPHI China || PMEC China 2024Asia Healthcare Week 2024Advance DoE WorkshopCPHI Korea 2024CHEMICAL INDONESIA 2024INALAB 2024 Thermo Scientific - DynaDrive and DynaSpinISPE Singapore Affiliate Conference & Exhibition 20242024 PDA Cell and Gene Pharmaceutical Products Conference 2024 PDA Aseptic Manufacturing Excellence Conference2024 PDA Aseptic Processing of Biopharmaceuticals Conference3rd World ADC Asia 2024LogiPharma Asia 2024